Caspofungin clinical trials
Caspofungin is named as an intervention in 2 current clinical trials in our China, USA, Germany, France, Spain, Italy, Belgium, Austria, Brazil, Japan, South Korea, Taiwan, Singapore, Australia and Israel registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Basilea Pharmaceutica (1). The most-studied condition is Candidemia. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Where Caspofungin is approved
All regulators →Of the three regulators tracked here, the first to approve Caspofungin was the US, on 26 Jan 2001. It is approved in 3 of the 3 regulators tracked here.
- 1 EU safety letter (DHPC), latest: post-authorisation measure for Caspofungin, 9 Oct 2025
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Caspofungin patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Caspofungin, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 21 Dec 2032 (US 9636407).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Caspofungin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Caspofungin works
All drug targets →- 1,3-beta-glucan synthase inhibitor InhibitorChEMBL only
- CandidemiaPhase 3
- Candidiasis, InvasivePhase 3
- Acute myeloid leukemiaPhase 3
- Myelodysplastic syndromePhase 3
- FeverPhase 2
- NeutropeniaPhase 2
- Oral candidiasisPhase 2
- PneumocystosisPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1630575, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Caspofungin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 12 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: Cancidas (previously Caspofungin MSD)EMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Caspofungin
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858 · Candidemia, Candidiasis, Invasive
|
Phase 3 | Recruiting | Basilea Pharmaceutica | USA, China, Germany, France, Spain, Italy, Belgium, Austria, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
PK/PD of Caspofungin in Children Severe Infection
NCT04961593 · Pharmacokinetics, Infection, Fungal
|
Observational | Recruiting | Children's Hospital of Fudan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Caspofungin in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Caspofungin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in uncomplicated candidemia: the CanTEN trial
2026-525640-14-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 4 | Authorised | University Of Cologne | Germany |
|
CANDISHORT : A randomized study of a short duration therapy for candidemia
2024-514244-81-00 · CTIS ↗ · Bacterial Infections and Mycoses
|
Phase 3 | Authorised | Assistance Publique Hopitaux De Paris | France |
Caspofungin across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
12 single-substance products containing Caspofungin on the HPRA medicines list.
- Caspofungin 50mg powder for concentrate for solution for infusionPinewood Laboratories Limited · PA0281/246/001 · Marketed
- Caspofungin 50mg powder for concentrate for solution for infusionDemo S.A. · PA1989/001/001 · Marketed
- Caspofungin 70mg powder for concentrate for solution for infusionPinewood Laboratories Limited · PA0281/246/002 · Marketed
- Caspofungin 70mg powder for concentrate for solution for infusionDemo S.A. · PA1989/001/002 · Marketed
- Caspofungin Clonmel 50 mg powder for concentrate for solution for infusionClonmel Healthcare Ltd · PA0126/341/001 · Marketed
Supply shortages
- Caspofungin Acetate InjectionUS (FDA) · Resolved · updated 30 Jun 2026
Conditions studied with Caspofungin
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Basilea Pharmaceutica | 1 |
| Children's Hospital of Fudan University | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Caspofungin trials
How many clinical trials are testing Caspofungin?
2 current trials in our China, USA, Germany, France, Spain, Italy, Belgium, Austria, Brazil, Japan, South Korea, Taiwan, Singapore, Australia and Israel registers name Caspofungin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Caspofungin trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in China, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Austria, 1 with sites in Brazil, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Singapore, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Caspofungin clinical trials?
Basilea Pharmaceutica (1) and Children's Hospital of Fudan University (1). The number in brackets is how many trials each organisation leads.
Is Caspofungin licensed in Ireland?
Yes. The HPRA medicines list includes 12 single-substance products containing Caspofungin, for example Caspofungin 50mg powder for concentrate for solution for infusion (Pinewood Laboratories Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Caspofungin shortage?
The registers we track list 1 entry for Caspofungin: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Caspofungin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Caspofungin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Caspofungin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.